cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Enzon, partner announce the filing of a new drug submission to Health Canada
December 14th, 2004
Enzon Pharmaceuticals, Inc. (ENZN) and Inex Pharmaceuticals Corp. (IEX) (INEX) announced that they have filed a new drug submission (NDS) with the Therapeutics Products directorate of Health Canada for Marqibo (formerly Onco TCS). The NDS is seeking marketing approval in Canada for Marqibo as a single-agent treatment for patients with relapsed aggressive non-Hodgkin lymphoma (NHL) previously treated with at least two combination chemotherapy regimens. INEX and Enzon will hear from the TPD within 45 days of filing as to whether the submission has been accepted for review. Subject to acceptance of the NDS for review, a response is anticipated from...
Source: cancer weekly (2004-12-14)
|
